WallStSmart

Merck & Company Inc (MRK)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 341483% more annual revenue ($67.38B vs $19.73M). ZJYL leads profitability with a 6.0% profit margin vs 3.6%. ZJYL trades at a lower P/E of 20.8x. MRK earns a higher WallStSmart Score of 42/100 (D).

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

ZJYL

Avoid

15

out of 100

Grade: F

Growth: 2.7Profit: 3.5Value: 5.3Quality: 5.5
Piotroski: 1/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-56.0%)

Margin of Safety

-56.0%

Fair Value

$85.13

Current Price

$133.72

$48.59 premium

UndervaluedFair: $85.13Overvalued

Intrinsic value data unavailable for ZJYL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

ZJYL1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

ZJYL4 concerns · Avg: 3.0/10
Market CapQuality
$628.82M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.4%3/10

ROE of 3.4% — below average capital efficiency

Profit MarginProfitability
6.0%3/10

6.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : ZJYL

The strongest argument for ZJYL centers on Price/Book.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : ZJYL

The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.

Key Dynamics to Monitor

ZJYL carries more volatility with a beta of 7.32 — expect wider price swings.

MRK is growing revenue faster at 4.7% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (42/100 vs 15/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.

Want to dig deeper into these stocks?